Giant cell arteritis (GCA) is a severe form of vasculitis in the elderly. The recent discovery of varicella zoster virus (VZV) in the temporal arteries and adjacent skeletal muscle of patients with GCA, and the rationale and strategy for antiviral and corticosteroid treatment for GCA are reviewed.
INTRODUCTION
Varicella zoster virus (VZV) is an exclusively human neurotropic alphaherpesvirus. Primary VZV infection causes varicella (chickenpox), after which virus becomes latent in ganglionic neurons along the entire neuraxis. Decades later, when VZVspecific cell-mediated immunity declines with age, virus reactivates, usually leading to zoster (dermatomal-distribution pain and rash). Often, zoster pain lasts for months or years (postherpetic neuralgia). Unfortunately, zoster can be further complicated by other serious neurological diseases, such as meningoencephalitis, cerebellitis, isolated or multiple cranial nerve palsies (polyneuritis cranialis), myelitis and vasculopathy, as well as multiple ocular disorders. Sequelae include paralysis, blindness and death. Importantly, as is characteristic of giant cell arteritis (GCA), all of the neurological and ocular disorders listed above may also develop in the absence of rash. The incidence and severity of zoster is best viewed as a continuum in immunodeficient individuals, ranging from a natural decline in VZV-specific immunity with advancing age to more serious host immune deficits as encountered in organ transplant recipients and patients with cancer or AIDS.
VZV is the only human virus that has been shown to replicate in arteries and cause disease. In intracerebral arteries, productive VZV infection leads to VZV vasculopathy [1, 2] . An exciting finding in the past few years is that productive VZV infection and vascular disease is not limited to the intracranial circulation; indeed, VZV infects extracranial temporal arteries and leads to GCA. The search for VZV in GCA was motivated by virtually identical pathological changes seen in the arteries of patients with both intracerebral VZV vasculopathy and GCA. In both conditions, the pathology is characterized by granulomatous arteritis, in which inflammation, often transmural, is seen with necrosis, usually in the arterial media, accompanied by multinucleated giant cells, epithelioid macrophages or both. The fact that granulomatous arteritis characterizes both intracerebral VZV vasculopathy and GCA, combined with the presence of VZV in cerebral arteries of VZV vasculopathy, prompted examination of temporal artery biopsies for VZV from patients with pathologically verified GCA as well as from patients with clinical features and laboratory abnormalities of GCA whose temporal artery biopsies were pathologically-negative for VZV.
CASE STUDIES
Historically, the role of VZV in GCA was suggested upon virological analysis of a temporal artery biopsy from an 80-year-old man who developed left ophthalmic-distribution zoster and ipsilateral ischemic optic neuropathy (ION) [3] . The temporal artery exhibited inflammation, but not GCA. VZV antigen was found primarily in the arterial adventitia and less so in the media of the temporal artery. The patient did not improve after treatment with steroids. After VZV was found in the temporal artery, the patient was immediately treated with intravenous acyclovir and his vision recovered. The patient was diagnosed with VZV-induced ION and subclinical temporal artery infection. Importantly, the location of VZV mostly in the arterial adventitia suggested that after reactivation from ganglia, virus spread transaxonally to the adventitia followed by transmural spread to the media.
The second patient was a 75-year-old woman who developed periorbital pain and blurred vision OS. There was no history of zoster rash. Visual acuity was 20/40 OD, 20/400 OS, with a mild left relative afferent pupillary defect [4] . The left optic nerve was swollen and hyperemic with peripapillary flame hemorrhages. ESR was 124 mm/h. She was treated with intravenous methylprednisolone, 250 mg q6 h. On day 3, headache and vision improved. Rheumatoid factor, ANA and ANCA titers were negative. On day 4, left temporal artery biopsy was GCA-negative and she began taking oral prednisone, 60 mg daily. Over the next week, pain and vision worsened, visual acuity was 20/400 OS with a relative left APD, and the left eye became blind and nonreactive to light; brain MRI with gadolinium and orbital computed tomography and head computed tomography angiography were negative. CSF contained 8 WBCs/mm 3 , protein 72 mg%, glucose 54 mg%; CSF cultures for bacteria, fungi, AFB and cytology were negative. Despite the absence of GCA pathology in the temporal artery, a VZV ION was diagnosed and she was treated with intravenous acyclovir, 10 mg/kg q8 h for 7 days. On day 31, the CSF contained anti-VZV IgG but not anti-HSV IgG antibody, and the serum-to-CSF ratio of anti-VZV IgG was markedly reduced (14) compared with normal ratios for total IgG (121) and albumin (81). Immunohistochemistry and pathology revealed VZV antigen and neutrophils in the original left temporal artery specimen. She was treated with oral valacyclovir, 1 g TID for 6 weeks; prednisone was reduced to 20 mg daily and tapered to 5 mg/week. Six weeks later, pain resolved and visual acuity improved to finger-counting. The left optic nerve was pale, with clear margins and resolution of hemorrhage. Essentially, another case of VZV ION
KEY POINTS
VZV is the only human virus shown to replicate in arteries and cause disease.
The pathology of intracerebral VZV vasculopathy and GCA is the same and characterized by granulomatous arteritis.
Productive VZV infection (herpesvirus virions, VZV antigen, and VZV DNA) is seen in intracerebral VZV vasculopathy and GCA.
The number of temporal artery sections examined for VZV is critical.
The distribution of VZV in the temporal artery and the presence of VZV in skip areas parallels the pathology in GCA.
The detection of VZV in some normal temporal arteries indicates subclinical VZV reactivation, not VZV latency.
Because VZV likely triggers the immunopathology of GCA, antiviral treatment is likely to confer additional benefit to corticosteroid-treated patients, although the optimal antiviral regimen remains to be determined.
Varicella zoster virus triggers the immunopathology Gilden and Nagel with sublinical temporal artery infection was uncovered, this time with no history of zoster rash.
The next link of VZV vasculopathy with features of GCA was provided by a 54-year-old diabetic woman who developed unilateral ION followed by acute retinal necrosis with multiple areas of focal venous beading [5] . The vitreous fluid contained amplifiable VZV DNA, but not HSV-1, CMV or toxoplasma DNA. The clinical presentation was remarkable for jaw claudication and intermittent scalp pain, prompting a temporal artery biopsy that was pathologically negative for GCA but notable for the presence of VZV antigen. The case added to the clinical spectrum of multifocal VZV vasculopathy.
DETECTION OF VARICELLA ZOSTER VIRUS IN GIANT CELL ARTERITY-NEGATIVE TEMPORAL ARTERIES
Further efforts to address the incidence of VZV infection in archived GCA biopsy-negative temporal arteries from study participants with clinically suspected GCA revealed VZV, but not HSV-1 antigen, in 5/24 (21%) temporal arteries [6] . Thirteen normal temporal arteries contained neither VZV nor HSV-1 antigen. Interestingly, all five subjects whose temporal arteries contained VZV antigen presented with clinical and laboratory features of GCA that included early visual disturbances. It then became clear that multifocal VZV vasculopathy can present with the full spectrum of clinical features and laboratory abnormalities characteristic of GCA, and that in GCA-negative/VZV-positive temporal arteries, viral antigen predominated in the arterial adventitia.
During the continuing search for VZV antigen in patients with GCA in whom temporal artery Bxs were negative, the temporal artery of one study participant revealed abundant VZV antigen and VZV DNA in multiple regions (skip areas) spanning 350 mm, as well as in skeletal muscle adjacent to the infected temporal artery; pathological analysis of sections adjacent to those containing viral antigen revealed inflammation involving the arterial media and abundant multinucleated giant cells characteristic of GCA [7] . In three other such cases, the detection of VZV in 'temporal artery Bx-negative GCA patients' led to additional pathological studies and a change in diagnosis to GCA.
RETROSPECTIVE ANALYSIS OF ARCHIVED GIANT CELL ARTERITY-POSITIVE AND NEGATIVE TEMPORAL ARTERIES FOR VARICELLA ZOSTER VIRUS
To test the hypothesis that VZV infection triggers the inflammatory cascade characteristic of GCA, formalin-fixed, paraffin-embedded GCA-positive temporal artery biopsies (50 sections/temporal artery), including adjacent skeletal muscle, and normal temporal artery biopsies from study participants more than 50 years of age were examined for the presence and distribution of VZV antigen by immunohistochemistry and ultrastructurally for virions; adjacent regions were examined by hematoxylineosin staining. VZV antigen-positive slides were also analyzed by PCR for VZV DNA. Initially, VZV antigen was detected in 61/82 (74%) GCA-positive temporal arteries compared with 1/13 (8%) normal temporal arteries (P < 0.0001). Most GCA-positive temporal arteries contained viral antigen ( Fig. 1a ) in skip areas [8 && ]. VZV antigen, present mostly in the arterial adventitia followed by the media and intima, was also detected skeletal muscles adjacent to VZV antigen-positive temporal arteries. Despite formalin fixation, VZV DNA was readily detected in 18/45 (40%) GCA-positive VZV antigen-positive temporal arteries; 6/10 (60%) VZV antigen-positive skeletal muscles; and 1 VZV antigen-positive normal temporal artery. VZ virions were also found in a GCA-positive temporal artery. GCA pathology in sections adjacent to those containing VZV was seen in 89% of GCA-positive temporal arteries, but not in any of 18 adjacent sections from normal temporal artery. Overall, most GCA-positive temporal arteries contained VZV in skip areas that correlated with adjacent GCA pathology. Moreover, transmission and scanning EM revealed herpesvirus particles in the same area that immunostained with anti-VZV antibody, and despite fixation, VZV DNA was readily amplifiable in many slides that contained VZV antigen. Together, the findings of VZV antigen, VZV DNA and VZ virions in temporal arteries indicate productive virus infection.
The search for VZV was extended to patients with clinically suspected GCA with histopathologically negative temporal artery biopsies [9 && ]. VZV antigen was found in 45/70 (64%) GCA-negative temporal arteries (Fig. 1b ) compared with 11/49 (22%) normal temporal arteries (P < .001), and extension of our earlier study revealed VZV antigen in 68/93 (73%) of GCA-positive temporal arteries compared with 11/ 49 (22%) normal temporal arteries (P < .001). Compared with normal temporal arteries, VZV antigen was more likely to be present in both GCA-Bxnegative temporal arteries (P < .001) and GCApositive temporal arteries (P < .001).
Continuing immunohistochemical analyses have to date revealed VZV antigen in 73/104 (70%) GCA-positive and 58/100 (58%) GCA-Bxnegative temporal arteries compared with 11/61 (18%) normal temporal arteries [10] . Overall, VZV antigen was 3.89-fold more likely to be present in GCA-positive temporal arteries than in normal temporal arteries (95% confidence interval ¼ 2.3819, 7.2384, P < 0.0001) and 3.22 times more likely to be present in GCA-Bx-negative temporal arteries than in normal temporal arteries (95% confidence interval ¼ 1.9391, 6.0303, P < 0.0001). All temporal arteries contained viral antigen in multiple arterial layers. In GCA-positive and GCA-Bx-negative study participants, viral antigen was seen in the adventitia (86 and 95%, respectively), media (67 and 53%, respectively) and intima (52 and 45%, respectively); in normal temporal arteries, viral antigen was seen in the adventitia (91%) and equally in media (82%) and intima (82%).
Examination of 58 GCA-positive, VZV antigenpositive temporal arteries for VZV DNA showed that all contained cellular DNA and 23 (40%) contained the viral DNA. Of 58 patients with GCA who were Bx-negative, VZV antigen-positive temporal arteries were examined. Fifty-one contained cellular DNA, of which nine (18%) contained VZV DNA. Nine of 11 normal VZV antigen-positive temporal arteries contained cellular DNA, of which three (33%) contained VZV DNA. Adventitial inflammation was seen adjacent to viral antigen in 26 (52%) of 58 GCA-Bx-negative study participants whose temporal arteries contained VZV antigen. No inflammation was seen in normal control temporal arteries containing VZV antigen.
Overall, the detection of VZV mostly in the adventitia of GCA-positive temporal arteries, together with the presence of VZV in the inflamed adventitia of GCA-Bx-negative temporal arteries, indicates that inflammation follows VZV reactivation from ganglia and transaxonal transport to arterial adventitia. The more detailed steps in the evolution of GCA (transmural inflammation and necrosis with giant and/or epithelioid cells) after virus infection of the adventitia and adventitial inflammation remain to be determined.
Another important finding in our studies is that the presence of VZV DNA and VZV antigen in 18% of control temporal arteries without inflammation indicates that VZV reactivates subclinically in some people over age 50. VZV DNA is found in latently infected human ganglia, but VZV expression is limited to the immediate-early VZV gene 63 RNA [11] . If VZV were latent in temporal arteries, only VZV DNA would be found, not VZV late glycoproteins and VZ virions.
Together, our data suggest that the prevalence of VZV in the temporal arteries of patients with clinically suspected GCA is similar, independent of whether biopsy is negative or positive Varicella zoster virus triggers the immunopathology Gilden and Nagel pathologically. Detection of adventitial inflammation adjacent to VZV antigen in 52% of GCA-Bx-negative temporal arteries for the first time connects the presence of VZV with pathology in GCA-Bx-negative temporal arteries. Inflammation restricted to the adventitia may represent a milder form of GCA [12] and has also been associated with ION [6, 13] . As noted above, we initially detected VZV in the temporal arteries of patients with ION whose biopsy revealed both adventitial and intimal inflammation but not classical GCA [3] .
In addition, we found that GCA-negative temporal artery biopsies contained VZV antigen in 5/7 (71%) patients with anterior ION (AION). Two VZV-positive, biopsy-negative AION cases had clinical features consistent with GCA. In one patient, GCA pathology was subsequently found adjacent to VZV antigen. Importantly, most patients with VZV-positive biopsies had atypical AION features (vascular gliosis at optic disc, subretinal hemorrhage and progressive vision loss), suggesting that VZV vasculopathy in AION produces a wider range of ischemia than in classical GCA. Owing to the multifocal nature of VZV vasculopathy and the rich innervation of the vascular supply to optic nerve and retina, VZV vasculopathy may produce a spectrum of ischemic injuries, such as anterior and posterior ION, retinal necrosis, and central retinal artery occlusion [4] [5] [6] . Thus, a search for VZV in atypical AION cases with elevated cup/disc ratios, pain, retinal pathology, or slow progression may identify individuals who could benefit from antiviral treatment. Additional prospective randomized controlled trials are needed to evaluate effects of antiviral therapy in these patients. Virological examination of temporal artery biopsies in AION patients with or without clinical and laboratory findings for GCA may reveal VZV infection, and should be included in the standard evaluation of AION patients. Extensive serial sections of temporal artery biopsies should be examined for both GCA pathology and for VZV antigen, since patients whose temporal arteries contain VZV may benefit from antiviral treatment.
NUMBER OF TEMPORAL ARTERY SECTIONS EXAMINED FOR VARICELLA ZOSTER VIRUS IS CRITICAL
Success in detecting VZV in temporal arteries was largely based on immunostaining of no fewer than 50 sections of every temporal artery in all studies above; immunohistochemistry using VZV-specific antibodies did not detect VZV antigen when only one section from each temporal artery was analyzed [14] . PCR in earlier studies to examine fixed GCA-positive and negative temporal arteries for VZV did not reveal VZV DNA when 1-6 sections per temporal artery were examined [14] [15] [16] [17] , whereas analysis of 4-6 sections detected VZV DNA in 9/35 (26%) GCA-positive temporal arteries [18] , and examination of 10 sections detected VZV DNA in 18/57 (32%) specimens from GCA-positive temporal arteries and in 18/56 (32%) of GCAnegative temporal arteries [19] . Furthermore, examination of 25 sections of each formalin-fixed temporal artery biopsy specimen revealed VZV antigen in 5/24 (21%) GCA-negative temporal arteries [20] . Overall, our detection of VZV antigen in most GCA-positive and GCA-Bx-negative temporal arteries indicates the value of staining many sections, most likely increasing detection of virus in skip regions. Immunostaining of several hundred sections of each GCA-positive temporal artery might reveal VZV in nearly all GCA-positive arteries.
DISTRIBUTION OF VARICELLA ZOSTER VIRUS IN THE TEMPORAL ARTERY AND PRESENCE OF VARICELLA ZOSTER VIRUS IN SKIP AREAS INFORM PATHOGENESIS
The consistently greater frequency of VZV in the adventitia than in the media and intima in GCApositive and GCA Bx-negative temporal arteries most likely reflects transaxonal transport of virus along afferent nerve fibers that innervate the temporal artery after reactivation from ganglia [20] . In GCA-positive temporal arteries, VZV in skip areas with inflammation is almost always associated with pathological features of GCA. The presence of VZV in skeletal muscle likely reflects the fact that the mammalian superficial temporal artery is richly innervated and that nociception in connective tissue of the temporalis muscle is relayed by afferent fibers with cell bodies in the trigeminal ganglia from which VZV reactivates. Interestingly, about 40% of patients with GCA have a history of polymyalgia rheumatica. Since muscle biopsy is not usually performed in these patients, the frequency of VZV infection in peripheral skeletal muscle is unknown.
FUTURE OF VARICELLA ZOSTER VIRUS ANTIGEN DETECTION IN GIANT CELL ARTERITY AND TREATMENT
As with GCA pathology, VZV antigen and inflammation are usually patchy and detected in only some sections. Our research-focused evaluation is not practical for routine diagnostic work-up of temporal artery biopsies. Although immunohistochemical evaluation is worthwhile, the absence of VZV antigen in the temporal artery does not rule out GCA or VZV reactivation since classic GCA pathology and viral antigen occur in skip lesions, which may be missed in analysis.
As for treatment of GCA, no trials have yet been conducted to determine whether antivirals and steroids confer additional benefit to steroids alone. Although many GCA patients improve with steroids, reports are legion of GCA patients who relapse with corticosteroid withdrawal, and may also develop more disseminated VZV vasculopathy and die [21 & ,22 & ]. Because VZV triggers the immunopathology of GCA, antiviral treatment is likely to confer additional benefit to corticosteroids. The optimal antiviral regimen remains to be determined. We currently treat GCA with prednisone, 1 mg/kg, along with valacyclovir, 1 g three times daily. If the patient improves after 4-6 weeks, we recommend tapering prednisone, while continuing administration of antiviral agents for another 4-6 weeks. Long-term antiviral drugs are far less risky than long-term corticosteroids. Furthermore, if during a prednisone taper, patients' symptoms recur or worsen, along with increases in ESR or CRP, oral antivirals should be added rather than increasing the prednisone dose. In our experience, antiviral treatment has successfully normalized symptoms and inflammatory markers. The value of our approach will have to be confirmed in large prospective studies.
VARICELLA ZOSTER VIRUS IN GRANULOMATOUS AORTITIS
Finally, because granulomatous arteritis characterizes the pathology of GCA, granulomatous aortitis, and intracerebral VZV vasculopathy, and because intracerebral VZV vasculopathy and GCA are strongly associated with productive VZV infection in cerebral and temporal arteries, respectively, we evaluated human aortas for VZV antigen and VZV DNA. Using three different anti-VZV antibodies, we identified VZV antigen in all 11 aortas with pathologically verified granulomatous aortitis (Fig. 2) , in one case of nongranulomatous aortitis and five out of 18 (28%) control aortas obtained at autopsy [23] . The presence of VZV antigen in granulomatous aortitis was highly significant (P ¼ 0.0001) as compared with control aortas, in which VZV antigen was never associated with pathology, indicating subclinical reactivation. VZV DNA was found in most aortas containing VZV antigen. The frequent clinical, radiological, and pathological aortic involvement in GCA patients correlates with the significant detection of VZV in granulomatous aortitis.
CONCLUSION
Virological analysis of temporal arteries from patients with pathologically verified GCA and temporal arteries from pathologically GCA-negative patients manifesting clinical and laboratory features of GCA revealed the presence of VZV in most GCA-positive and GCA-temporal artery Bx-negative specimens. In GCA-positive temporal arteries, VZV was especially noted in skip areas that correlate with adjacent GCA pathology. The presence of VZV in GCA-positive and GCA-Bx-negative temporal arteries shows that VZV triggers the immunopathology of GCA and implies the need for treatment in both groups of patients with antiviral drugs in addition to corticosteroids. It is not known whether oral or intravenous antiviral agents plus (a) (b) (c) FIGURE 2. Varicella zoster virus (VZV) antigen in pathologically verified granulomatous arteritis. Immunostaining with a monoclonal mouse anti-VZV gE IgG1 antibody revealed VZV antigen in the adventitia of an aorta from a patient with pathologically verified granulomatous arteritis (a, pink color). No staining was seen when mouse IgG1 isotype control antibody was substituted for the primary anti-VZV antibody (b). Hematoxylin and eosin staining of another aorta that contained VZV antigen showed classic granulomatous arteritis pathology: inflammation in the adventitia and media with medial necrosis (c) and giant cells (c, arrow and inset). Magnification 600 (a and b) and 100 (c). IgG1, immunoglobulinG1.
Varicella zoster virus triggers the immunopathology Gilden and Nagel corticosteroids are equally effective. Appropriate dosage and duration of treatment also remains to be determined.
